4/A: Ionis Pharmaceuticals Executive Corrects Stock Sale Reporting
SEC Filing
Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, amends a previous Form 4 filing to correct the number of shares sold and beneficially owned.
Summary
- Richard S. Geary, an executive at Ionis Pharmaceuticals, filed an amended Form 4 with the SEC.
- The amendment corrects a previous filing from February 2, 2024, regarding the sale of restricted stock units.
- The corrected filing shows that 1,995 shares were sold at a weighted average price of $50.0433.
- The sales occurred in multiple transactions with prices ranging from $49.80 to $50.30.
- Following the reported transaction, Mr. Geary beneficially owns 87,300 shares of Ionis Pharmaceuticals stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in reporting is always viewed favorably.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- Shareholders benefit from accurate and transparent reporting of insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date of original transaction and initial Form 4 filing. |
| 02/02/2024 | Date of amended Form 4 filing. |
| 09/04/2024 | Date of signature on the amended Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.